Multicentre surveillance study on feasibility, safety and efficacy of antifungal combination therapy for proven or probable invasive fungal diseases in haematological patients: The SEIFEM real-life combo study

Mycoses

Volumn 57, Issue 6, 2014, Pages 342-350

  Candoni, A ^a   Caira, M ^b   Cesaro, S ^c,d   Busca, A ^c,e   Giacchino, M ^c,f   Fanci, R ^c,g   Delia, M ^c,h   Nosari, A ^c,i   Bonini, A ^c,j   Cattaneo, C ^c,k   Melillo, L ^c,l   Caramatti, C ^c,m   Milone, G ^c,n   Scime', R ^c,o   Picardi, M ^c,p   Fanin, R ^a   Pagano, L ^b  

^a UNIVERSITY OF UDINE   (Italy)

^b CATHOLIC UNIVERSITY   (Italy)

^c SEIFEM Group   (Italy)

^d Pediatric Hematology Oncology AOU Integrata   (Italy)

^e AOU San Giovanni Battista   (Italy)

^f REGINA MARGHERITA CHILDREN S HOSPITAL   (Italy)

^g UNIVERSITY OF FLORENCE   (Italy)

^h UNIVERSITY OF BARI   (Italy)

ⁱ OSPEDALE NIGUARDA CA GRANDA   (Italy)

^j S MARIA NUOVA HOSPITAL   (Italy)

^k UO Ematologia   (Italy)

^l CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

^m Ematologia CTMO AOU Parma   (Italy)

ⁿ Ospedale Ferrarotto   (Italy)

^o LA MADDALENA CANCER CENTER   (Italy)

^p UNIVERSITY OF NAPLES FEDERICO II   (Italy)

more..

Author keywords

Amphothericin; Caspofungin; Combined antifungal therapy; Invasive fungal disease; Posaconazole; Voriconazole

Indexed keywords

ALANINE AMINOTRANSFERASE; AMPHOTERICIN B LIPID COMPLEX; ASPARTATE AMINOTRANSFERASE; CASPOFUNGIN; FLUCONAZOLE; ITRACONAZOLE; POSACONAZOLE; VORICONAZOLE; ANTIFUNGAL AGENT;

ADOLESCENT; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASPERGILLUS; CANDIDA; CHILD; DRUG EFFICACY; DRUG SAFETY; FEMALE; GRANULOCYTE; HUMAN; HYPOKALEMIA; LEUKEMIA; LUNG INFECTION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OBSERVATIONAL STUDY; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; SYSTEMIC MYCOSIS; YOUNG ADULT; ZYGOMYCETES; CLINICAL TRIAL; COMPLICATION; DRUG COMBINATION; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HEMATOLOGIC DISEASE; INCIDENCE; INFANT; ITALY; MULTICENTER STUDY; MYCOSES; PATHOLOGY; SURVIVAL; TREATMENT OUTCOME;

ASPERGILLUS SP.; CANDIDA; FUSARIUM SP.; ZYGOMYCETES;

ADOLESCENT; ADULT; AGED; ANTIFUNGAL AGENTS; CHILD; CHILD, PRESCHOOL; DRUG THERAPY, COMBINATION; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HEMATOLOGIC NEOPLASMS; HUMANS; INCIDENCE; INFANT; ITALY; MALE; MIDDLE AGED; MYCOSES; SURVIVAL ANALYSIS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84900500584     PISSN: 09337407     EISSN: 14390507     Source Type: Journal    
DOI: 10.1111/myc.12161     Document Type: Article

References (40)

1. Pagano L, Caira M, Picardi M, et al. Invasive Aspergillosis in patients with acute leukemia: update on morbidity and mortality-SEIFEM-C report. Clin Infect Dis 2007; 44: 1524-5.
2. Neofytos D, Horn D, Anaissie E, et al. Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: analysis of Multicenter Prospective Antifungal Therapy (PATH) alliance registry. Clin Infect Dis 2009; 48: 265-73.
3. Pagano L, Valentini CG, Posteraro B, et al. Zygomycosis in Italy: a survey of FIMUA-ECMM (Federazione Italiana di Micopatologia Umana ed Animale and European Confederation of Medical Mycology). J Chemother 2009; 21:322-9.
4. Maschmeyer G, Haas A, Cornely OA. Invasive aspergillosis: epidemiology, diagnosis and management in immunocompromised patients. Drugs 2007; 67: 1567-604.
5. Bennett JE, Dismukes WE, Duma RJ, et al. A comparison of amphotericin B alone and combined with flucytosine in the treatment of cryptoccal meningitis. N Engl J Med 1979; 301: 126-31.
6. Day JN, Chau IT, Lalloo DG. Combination antifungal therapy for Cryptococcal Meningitis. N Engl J Med 2013; 368: 2522-3.
7. Petraitis V, Petraitiene R, Sarafandi AA, et al. Combination therapy in treatment of experimental pulmonary aspergillosis: synergistic interaction between an antifungal triazole and an echinocandin. J Infect Dis 2003; 187: 1834-43.
8. Arikan S, Lozano-Chiu M, Paetznick V, Rex JH. In vitro synergy of caspofungin and amphotericin B against Aspergillus and Fusarium spp. Antimicrob Agents Chemother 2002; 46: 245-7.
9. Kirkpatrick WR, Coco BJ, Patterson TF. Sequential or combination antifungal therapy with voriconazole and liposomal amphotericin B in a guinea pig model of invasive aspergillosis. Antimicrob Agents Chemother 2006; 50: 1567-9.
10. MacCallum DM, Whyte JA, Odds FC. Efficacy of caspofungin and voriconazole combinations in experimental aspergillosis. Antimicrob Agents Chemother 2005; 49: 3697-701.
11. Petraitis V, Petraitiene R, Hope WW, et al. Combination therapy in treatment of experimental pulmonary aspergillosis: in vitro and in vivo correlations of the concentration- and dose- dependent interactions between anidulafungin and voriconazole by Bliss independence drug interaction analysis. Antimicrob Agents Chemother 2009; 53: 2382-91.
12. Ibrahim AS, Gebremariam T, Fu Y, et al. Combination echinocandin-polyene treatment of murine mucormycosis. Antimicrob Agents Chemother 2008; 52: 1556-8.
13. Manavathu EK, Alangaden GJ, Chandrasekar PH. Differential activity of triazoles in two-drug combinations with the echinocandin caspofungin against Aspergillus fumigatus. J Antimicrob Chemother 2003; 51: 1423-5.
14. Ascioglu S, Rex JH, de Pauw B, et al. Defining opportunistic invasive fungal infections in immune-compromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 2002; 34: 7-14.
15. Segal BH, Herbrecht R, Stevens DA, et al. Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer consensus criteria. Clin Infect Dis 2008; 47: 674-83.
16. Lewis RE. Decision making in antifungal monotherapy versus combination therapy. Pharmacotherapy 2006; 26: 61-67.
17. Lewis RE, Kontoyiannis DP. Rationale for combination antifungal therapy. Pharmacotherapy 2001; 21: 149-64.
18. Kontoyiannis DP, Lewis RE. Toward more effective antifungal therapy: the prospects of combination therapy. Br J Haematol 2004; 126: 165-75.
19. Johnson MD. Perfect JR Combination antifungal therapy: what can and should we expect ? Bone Marrow Transplant 2007; 40: 297-306.
20. Powers JH. Considerations in clinical trials of combination antifungal therapy. Clin Infect Dis 2004; 39(Suppl 4): S228-35.
21. Walsh TJ, Anaissie EJ, Denning DW, et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2008; 46: 327-60.
22. Pappas PG, Kauffman CA, Andes D, et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009; 48: 503-35.
23. Maertens J, Marchetti O, Herbrecht R, et al. Third European Conference on Infections in Leukemia. European guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients: summary of the ECIL 3-2009 update. Bone Marrow Transplant 2011; 46: 709-18.
24. Böhme A, Ruhnke M, Buchheidt D, et al. Treatment of invasive fungal infections in cancer patients-recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol 2009; 88: 97-110.
25. Maertens J, Glasmacher A, Herbrecht R, et al. Multicenter, noncomparative study of caspofungin in combination with other antifungals as salvage therapy in adults with invasive aspergillosis. Cancer 2006; 107: 2888-97.
26. Caillot D, Thiebaut A, Herbrecht R, et al. Liposomal amphotericin B in combination with caspofungin for invasive aspergillosis in patients with hematologic malignancies: a randomized pilot study (Combistrat trial). Cancer 2007; 110: 2740-6.
27. Kontoyiannis DP, Hachem R, Lewis RE, et al. Efficacy and toxicity of caspofungin in combination with liposomal amphotericin B as primary or salvage treatment of invasive aspergillosis in patients with hematologic malignancies. Cancer 2003; 98: 292-9.
28. Aliff TB, Maslak PG, Iurcic JC, et al. Refractory Aspergillus pneumonia in patients with acute leukemia: successful therapy with combination caspofungin and liposomal amphotericin. Cancer 2003; 97: 1025-32.
29. Marr KA, Boeckh M, Carter RA, et al. Combination antifungal therapy for invasive aspergillosis. Clin Infect Dis 2004; 39: 797-802.
30. Rojas R, Molina JR, Jarque I, et al. Outcome of antifungal combination therapy for invasive mold infections in hematological patients is indipendent of the chosen combination. Med J Hem Infect Dis 2012; 4: 1-8.
31. Kontoyiannis DP, Boktour M, Hanna H, Torres HA, Hachem R, Raad II. Itraconazole added to a lipid formulation of amphotericin B does not improve outcome of primary treatment of invasive aspergillosis. Cancer 2005; 103: 2334-7.
32. Rieger CT, Ostermann H, Kolb HJ, et al. A clinical cohort trial of antifungal combination therapy: efficacy and toxicity in haematological cancer patients. Ann Hematol 2008; 87: 915-22.
33. Kontoyiannis DP, Ratanatharathorn V, Young JA, et al. Micafungin alone or in combination with other systemic antifungal therapies in HSCT recipients with invasive aspergillosis. Transpl Infect Dis 2009; 11: 89-93.
34. Mihu CN, Kassis C, Ramos ER, Jiang Y, Hachem RY, Raad II. Does combination of lipid formulation of amphotericin B and echinocandins improve outcome of invasive aspergillosis in hematological malignancy patients ? Cancer 2010; 116: 5290-6.
35. Lellek H, Waldenmaier D, Dahlke J, et al. Caspofungin plus Posaconazole as salvage therapy of invasive fungal infections in immunocompromised patients. Mycoses 2011; 54: 39-44.
36. Pagano L, Cornely O, Busca A, et al. Combined antifungal approach for the treatment of invasive mucormycosis in patients with hematological diseases: a report from the SEIFEM and FUNGISCOPE registries. Haematologica 2013; 98: 127-30.
37. Marr KA, Schlamm H, Rottinghaus ST, et al. A randomised, double-blind study of combination antifungal therapy with voriconazole and anidulafungin versus voriconazole monotherapy for primary treatment of invasive aspergillosis. abstr LB 2812. Abstr. In 22nd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), London, March 2012.
38. Pfaller MA, Messer SA, Woosley LN, Jones RN, Castanheira M. Echinocandin and triazole antifungal susceptibility profiles of opportunistic yeast and mould clinical isolates (2010-2011): application of new CLSI clinical breakpoints and epidemiological cutoff values to characterize geographic and temporal trends of antifungal resistance. J Clin Microbiol 2013; 51: 2571-81.
39. Even C, Bastuji-Garin S, Hicheri Y, et al. Impact of invasive fungal disease on the chemotherapy schedule and event-free survival in acute leukemia patients who survived fungal disease: a case-control study. Haematologica 2011; 96: 337-41.
40. Lewis RE, Georgiadou SP, Sampsonas F, Chamilos G, Kontoyiannis DP. Risk factors for early mortality in haematological malignancy patients with pulmonary mucormycosis. Mycoses 2013; doi: 10.1111/myc.12101.